Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 191


Long-term safety follow-up of a randomized trial of darbepoetin alpha and intravenous iron following autologous hematopoietic cell transplantation.

Jaspers A, Baron F, Maertens J, De Prijck B, Schots R, Bonnet C, Hafraoui K, Willems É, Servais S, Fillet G, Beguin Y.

Am J Hematol. 2015 Jul;90(7):E133-4. doi: 10.1002/ajh.24013. No abstract available.


High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.

Willemze R, Suciu S, Meloni G, Labar B, Marie JP, Halkes CJ, Muus P, Mistrik M, Amadori S, Specchia G, Fabbiano F, Nobile F, Sborgia M, Camera A, Selleslag DL, Lefrère F Sr, Magro D, Sica S, Cantore N, Beksac M, Berneman Z, Thomas X, Melillo L, Guimaraes JE, Leoni P, Luppi M, Mitra ME, Bron D, Fillet G, Marijt EW, Venditti A, Hagemeijer A, Mancini M, Jansen J, Cilloni D, Meert L, Fazi P, Vignetti M, Trisolini SM, Mandelli F, de Witte T.

J Clin Oncol. 2014 Jan 20;32(3):219-28. doi: 10.1200/JCO.2013.51.8571. Epub 2013 Dec 2.


Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation: a prospective multicenter randomized trial.

Beguin Y, Maertens J, De Prijck B, Schots R, Seidel L, Bonnet C, Hafraoui K, Willems E, Vanstraelen G, Servais S, Jaspers A, Fillet G, Baron F.

Am J Hematol. 2013 Dec;88(12):990-6. doi: 10.1002/ajh.23552. Epub 2013 Sep 30.


A novel mutation in the CUB sequence of matriptase-2 (TMPRSS6) is implicated in iron-resistant iron deficiency anaemia (IRIDA).

Jaspers A, Caers J, Le Gac G, Ferec C, Beguin Y, Fillet G.

Br J Haematol. 2013 Feb;160(4):564-5. doi: 10.1111/bjh.12147. Epub 2012 Dec 6. No abstract available.


Diffuse large B-cell lymphoma of Waldeyer's ring has distinct clinicopathologic features: a GELA study.

de Leval L, Bonnet C, Copie-Bergman C, Seidel L, Baia M, Brière J, Molina TJ, Fabiani B, Petrella T, Bosq J, Gisselbrecht C, Siebert R, Tilly H, Haioun C, Fillet G, Gaulard P.

Ann Oncol. 2012 Dec;23(12):3143-51. doi: 10.1093/annonc/mds150. Epub 2012 Jun 13.


CHIC cells: a novel ALK+ cell line derived from a relapsed anaplastic large cell lymphoma.

Thielen C, Bisig B, Gofflot S, Herens C, Fillet G, Jamar M, Tassin F, Boniver J, Drion P, de Leval L.

Br J Haematol. 2011 Feb;152(3):356-60. doi: 10.1111/j.1365-2141.2010.08414.x. Epub 2010 Oct 19. No abstract available.


Dexamethasone compared to prednisolone for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma: final results of the ALL-4 randomized, phase III trial of the EORTC Leukemia Group.

Labar B, Suciu S, Willemze R, Muus P, Marie JP, Fillet G, Berneman Z, Jaksic B, Feremans W, Bron D, Sinnige H, Mistrik M, Vreugdenhil G, De Bock R, Nemet D, Gilotay C, Amadori S, de Witte T; EORTC Leukemia Group.

Haematologica. 2010 Sep;95(9):1489-95. doi: 10.3324/haematol.2009.018580. Epub 2010 Apr 7.


Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.

Baron F, Lechanteur C, Willems E, Bruck F, Baudoux E, Seidel L, Vanbellinghen JF, Hafraoui K, Lejeune M, Gothot A, Fillet G, Beguin Y.

Biol Blood Marrow Transplant. 2010 Jun;16(6):838-47. doi: 10.1016/j.bbmt.2010.01.011. Epub 2010 Jan 28.


[Current treatment of follicular lymphoma].

Bonnet C, Beguin Y, Deprijck B, de Leval L, Fillet G.

Rev Med Suisse. 2009 Aug 26;5(214):1663-7. Review. French.


Comparison of thrombotic microangiopathy after allogeneic hematopoietic cell transplantation with high-dose or nonmyeloablative conditioning.

Willems E, Baron F, Seidel L, Frère P, Fillet G, Beguin Y.

Bone Marrow Transplant. 2010 Apr;45(4):689-93. doi: 10.1038/bmt.2009.230. Epub 2009 Aug 31.


[Monoclonal antibodies and breast cancer. Current therapeutic progress].

Collignon J, Gennigens C, Rorive A, Coucke P, Lifrange E, Maweja S, Fillet G, Jerusalem G.

Rev Med Liege. 2009 May-Jun;64(5-6):279-83. French.


[Monoclonal antibodies in hematology in 2009].

Bonnet C, Beguin Y, De Prijck B, Witvrouw N, Hustinx R, Fillet G.

Rev Med Liege. 2009 May-Jun;64(5-6):268-73. French.


[Radiation recall dermatitis after oral cyclophosphamide].

Mievis C, Jansen N, Schleich F, Gennigens C, Rorive A, Jérusalem G, Fillet G, Sautois B.

Rev Med Liege. 2009 Apr;64(4):179-81. French.


Selective defect of anti-pneumococcal IgG in a patient with persistent polyclonal B cell lymphocytosis.

Hafraoui K, Moutschen M, Smet J, Mascart F, Schaaf-Lafontaine N, Fillet G.

Eur J Intern Med. 2009 May;20(3):e62-5. doi: 10.1016/j.ejim.2008.08.005. Epub 2008 Oct 1.


Non-myeloablative transplantation with CD8-depleted or unmanipulated peripheral blood stem cells: a phase II randomized trial.

Willems E, Baron F, Baudoux E, Wanten N, Seidel L, Vanbellinghen JF, Herens C, Gothot A, Frère P, Bonnet C, Hafraoui K, Vanstraelen G, Fillet G, Beguin Y.

Leukemia. 2009 Mar;23(3):608-10. doi: 10.1038/leu.2008.248. Epub 2008 Sep 18. No abstract available.


A randomized multicenter study of optimal circadian time of vinorelbine combined with chronomodulated 5-fluorouracil in pretreated metastatic breast cancer patients: EORTC trial 05971.

Coudert B, Focan C, Genet D, Giacchetti S, Cvickovic F, Zambelli A, Fillet G, Chollet P, Amoroso D, Van Der Auwera J, Lentz MA, Marreaud S, Baron B, Gorlia T, Biville F, Lévi F.

Chronobiol Int. 2008 Sep;25(5):680-96. doi: 10.1080/07420520802384036.


[How I treat... Acute myeloid leukemia in older patients with good performance status].

Lejeune M, Beguin Y, De Prijck B, Fassotte MF, Fillet G, Baron F.

Rev Med Liege. 2008 Feb;63(2):59-63. French.


[Targeted therapies in breast cancer: current status and perspectives].

Jerusalem G, Rorive A, Gennigens C, Sautois B, Mievis C, Fillet G.

Rev Med Liege. 2007;62 Spec No:2-5. Review. French.


[Chemotherapy of ovarian cancer: state of the art].

Paulus A, Gennigens C, Fillet G, Loly C, Sautois B.

Rev Med Liege. 2007 Sep;62(9):539-47. Review. French.


[Current therapeutic progress in oncology: the development of targeted therapies].

Gennigens C, Sautois B, Rorive A, Fillet G, Jerusalem G.

Rev Med Liege. 2007 May-Jun;62(5-6):391-8. Review. French.


[Current therapies in hematology].

De Prijck B, Baron F, Beguin Y, Bonnet C, Willems E, Fillet G.

Rev Med Liege. 2007 May-Jun;62(5-6):384-90. Review. French.


Thoracic extramedullary hematopoiesis secondary to enzymatic deficiency.

Monville JF, Fillet G, Ghaye B.

JBR-BTR. 2007 May-Jun;90(3):198-9. No abstract available.


Limited usefulness of CA125 measurement in the management of Hodgkin's and non-Hodgkin's lymphoma.

Bonnet C, Beguin Y, Fassotte MF, Seidel L, Luyckx F, Fillet G.

Eur J Haematol. 2007 May;78(5):399-404. Epub 2007 Apr 5.


Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study.

Thomas X, Suciu S, Rio B, Leone G, Broccia G, Fillet G, Jehn U, Feremans W, Meloni G, Vignetti M, de Witte T, Amadori S.

Haematologica. 2007 Mar;92(3):389-96.


CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte.

Bonnet C, Fillet G, Mounier N, Ganem G, Molina TJ, Thiéblemont C, Fermé C, Quesnel B, Martin C, Gisselbrecht C, Tilly H, Reyes F; Groupe d'Etude des Lymphomes de l'Adulte.

J Clin Oncol. 2007 Mar 1;25(7):787-92. Epub 2007 Jan 16.


Diagnostic and therapeutic management of carcinoma of unknown primary: radio-imaging investigations.

Jerusalem G, Rorive A, Ancion G, Hustinx R, Fillet G.

Ann Oncol. 2006 Sep;17 Suppl 10:x168-76. Review. No abstract available.


Non-infusional vs intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: final results of the EORTC-GIMEMA AML-13 randomized phase III trial.

Jehn U, Suciu S, Thomas X, Lefrère F, Muus P, Berneman Z, Marie JP, Adamo F, Fillet G, Nobile F, Ricciuti F, Leone G, Rizzoli V, Montanaro M, Beeldens F, Fazi P, Mandelli F, Willemze R, de Witte T, Amadori S.

Leukemia. 2006 Oct;20(10):1723-30. Epub 2006 Aug 17.


Recombinant human erythropoietin therapy after allogeneic hematopoietic cell transplantation with a nonmyeloablative conditioning regimen: low donor chimerism predicts for poor response.

Vanstraelen G, Baron F, Willems E, Bonnet C, Hafraoui K, Frère P, Fillet G, Beguin Y.

Exp Hematol. 2006 Jul;34(7):841-50.


Pegfilgrastim compared with Filgrastim after autologous hematopoietic peripheral blood stem cell transplantation.

Vanstraelen G, Frère P, Ngirabacu MC, Willems E, Fillet G, Beguin Y.

Exp Hematol. 2006 Mar;34(3):382-8.


[Hic et Nunc. Naevus or melanoma?].

Piérard-Franchimont C, Piérard GE, Quatresooz P, Arrese JE, Rorive A, Fillet G; Grope Mosan d'Etude des Tumeurs Pigmentaires.

Rev Med Liege. 2006 Jan;61(1):43-7. French.


[Image of the month. Macronodular lesions of the lung].

Wauters O, Sautois B, Fillet G.

Rev Med Liege. 2005 Dec;60(12):909-10. French. No abstract available.


Infections after allogeneic hematopoietic stem cell transplantation with a nonmyeloablative conditioning regimen.

Frère P, Baron F, Bonnet C, Hafraoui K, Pereira M, Willems E, Fillet G, Beguin Y.

Bone Marrow Transplant. 2006 Feb;37(4):411-8.


Infections after CD34-selected or unmanipulated autologous hematopoietic stem cell transplantation.

Frère P, Pereira M, Fillet G, Beguin Y.

Eur J Haematol. 2006 Feb;76(2):102-8.


[Anemia by self-injury: the Lasthenie de Ferjol syndrome].

Farcy L, Fillet G, Couvreur V, Triffaux JM.

Rev Med Liege. 2005 Sep;60(9):719-23. French.


[Nonmyeloablative stem cell transplantation as cancer immunotherapy].

Willems E, Baron F, Vanstraelen G, Frère P, Fillet G, Beguin Y.

Rev Med Suisse. 2005 Aug 24;1(30):1973-7. Review. French.


Efficacy of recombinant human erythropoietin therapy started one month after autologous peripheral blood stem cell transplantation.

Vanstraelen G, Baron F, Frère P, Hafraoui K, Fillet G, Beguin Y.

Haematologica. 2005 Sep;90(9):1269-70.


Evaluation of therapy for lymphoma.

Jerusalem G, Hustinx R, Beguin Y, Fillet G.

Semin Nucl Med. 2005 Jul;35(3):186-96. Review.


Positron emission tomography imaging for lymphoma.

Jerusalem G, Hustinx R, Beguin Y, Fillet G.

Curr Opin Oncol. 2005 Sep;17(5):441-5. Review.


[Image of the month. Splenic cyst].

Bonaventure S, Scagnol I, Linder JL, Fillet G, Boniver J, de Leval L.

Rev Med Liege. 2005 Jan;60(1):5-6. French. No abstract available.


Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study.

Amadori S, Suciu S, Jehn U, Stasi R, Thomas X, Marie JP, Muus P, Lefrère F, Berneman Z, Fillet G, Denzlinger C, Willemze R, Leoni P, Leone G, Casini M, Ricciuti F, Vignetti M, Beeldens F, Mandelli F, De Witte T; EORTC/GIMEMA Leukemia Group.

Blood. 2005 Jul 1;106(1):27-34. Epub 2005 Mar 10.


CD34+ cell dose predicts costs after autologous peripheral blood stem cell transplantation for breast cancer.

Baron F, Copizza S, Baudoux E, Jerusalem G, Fillet G, Beguin Y.

Haematologica. 2004 Sep;89(9):1146-8.


Allogeneic stem cell transplantation in acute lymphoblastic leukemia and non-Hodgkin's lymphoma for patients <or=50 years old in first complete remission: results of the EORTC ALL-3 trial.

Labar B, Suciu S, Zittoun R, Muus P, Marie JP, Fillet G, Peetermans M, Stryckmans P, Willemze R, Feremans W, Jaksic B, Bourhis JH, Burghouts JP, de Witte T; EORTC Leukemia Group.

Haematologica. 2004 Jul;89(7):809-17.


[Image of the month. Merkel cell tumor: response to chemotherapy].

Polus M, Piront P, Jerusalem G, Sautois B, Defechereux T, de Leval L, Fillet G.

Rev Med Liege. 2004 Feb;59(2):67-8. French. No abstract available.


Bacteremia after hematopoietic stem cell transplantation: incidence and predictive value of surveillance cultures.

Frère P, Hermanne JP, Debouge MH, de Mol P, Fillet G, Beguin Y.

Bone Marrow Transplant. 2004 Apr;33(7):745-9.


T-cell reconstitution after unmanipulated, CD8-depleted or CD34-selected nonmyeloablative peripheral blood stem-cell transplantation.

Baron F, Schaaf-Lafontaine N, Humblet-Baron S, Meuris N, Castermans E, Baudoux E, Frère P, Bours V, Fillet G, Beguin Y.

Transplantation. 2003 Dec 27;76(12):1705-13.


Low T-cell chimerism is not followed by graft rejection after nonmyeloablative stem cell transplantation (NMSCT) with CD34-selected PBSC.

Baron F, Baudoux E, Frère P, Tourqui S, Schaaf-Lafontaine N, Herens C, DePrijck B, Fillet G, Beguin Y.

Bone Marrow Transplant. 2003 Oct;32(8):829-34.


Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.

Tilly H, Lepage E, Coiffier B, Blanc M, Herbrecht R, Bosly A, Attal M, Fillet G, Guettier C, Molina TJ, Gisselbrecht C, Reyes F; Groupe d'Etude des Lymphomes de l'Adulte.

Blood. 2003 Dec 15;102(13):4284-9. Epub 2003 Aug 14.


[Primary and secondary prevention of colorectal cancer].

Polus M, Piront P, Jerusalem G, Sautois B, Louis E, Detroz B, Laurent S, Belaiche J, Fillet G.

Rev Med Liege. 2003 Apr;58(4):247-53. Review. French.

Supplemental Content

Loading ...
Support Center